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Background: Human respiratory syncytial virus (hRSV) is a highly contagious pathogen and is the most common
cause of bronchiolitis and pneumonia for infants and children under one year of age. Worldwide, greater than 33
million children under five years of age are affected by hRSV resulting in three million hospitalizations and 200,000
deaths. However, severe lower respiratory tract disease may occur at any age, especially among the elderly or those
with compromised cardiac, pulmonary, or immune systems. There is no vaccine commercially available. Existing
therapies for the acute infection are ribavirin and the prophylactic humanized monoclonal antibody (SynagisW from
MedImmune) that is limited to use in high risk pediatric patients. Thus, the discovery of new inhibitors for hRSV
would be clinically beneficial.
Results: We have developed and validated a 384-well cell-based, high-throughput assay that measures the
cytopathic effect of hRSV (strain Long) in HEp-2 cells using a luminescent-based detection system for signal
endpoint (Cell Titer GloW). The assay is sensitive and robust, with Z factors greater than 0.8, signal to background
greater than 35, and signal to noise greater than 24. Utilizing this assay, 313,816 compounds from the Molecular
Libraries Small Molecule Repository were screened at 10 μM. We identified 7,583 compounds that showed greater
than 22% CPE inhibition in the primary screen. The top 2,500 compounds were selected for confirmation screening
and 409 compounds showed at least 50% inhibition of CPE and were considered active. We selected fifty-one
compounds, based on potency, selectivity and chemical tractability, for further evaluation in dose response and
secondary assays Several compounds had SI50 values greater than 3, while the most active compound displayed an
SI50 value of 58.9.
Conclusions: A robust automated luminescent-based high throughput screen that measures the inhibition of
hRSV-induced cytopathic effect in HEp-2 cells for the rapid identification of potential inhibitors from large
compound libraries has been developed, optimized and validated. The active compounds identified in the screen
represent different classes of molecules, including aryl sulfonylpyrrolidines which have not been previously
identified as having anti-hRSV activity.
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Human respiratory syncytial viruses (hRSV) infect the
lower respiratory tract and cause substantial morbidity
and mortality annually [1]. hRSV disease is the most
common cause of bronchiolitis and pneumonia among
infants and children under one year of age [1]. Globally,
there are approximately 3 million hospitalizations of
children under five years of age and 200,000 deaths due
to hRSV or its complications each year [2]. Even so,
hRSV disease may occur at any age and severe disease
can affect those individuals who have chronic obstruct-
ive pulmonary disease (COPD) and the immunocom-
promised [3]. In the United States, the economic impact
of hRSV infections due to direct and indirect medical
costs is greater than $650 million annually [4].
hRSV is a negative sense, single-stranded, non-segmented
enveloped RNA virus of approximately 15 kb [5]. Ten viral
genes encode 11 viral proteins that are transcribed from
the viral RNA (vRNA). Three essential glycoproteins pro-
trude from the membrane. The G-protein is thought to
mediate attachment to long unbranched polysaccharides of
the extracellular matrix composed of glycoaminoglycans
(GAGs); however, virus that has a deletion of the G protein
is able to replicate in tissue culture [6,7]. The fusion (F)
protein is essential for fusion of the virus envelope with the
cell membrane and entry of the virus into the cell cyto-
plasm through the interaction with protein RhoA. The
small hydrophobic (SH) protein, a phosphoprotein, forms
homopentamers suggesting it acts as a viroporin contribut-
ing to infection and replication [8,9]. The inner leaflet
of the virion contains the mature (M) protein that coor-
dinates the assembly of the virion. The viral core is
composed of a nucleocapsid (N) protein that encapsidates
the vRNA and binds to the L protein or RNA-dependent
RNA polymerase (RdRp), phosphoprotein (P), and the tran-
scription anti-terminator factor (M2-1) [10-12] to form the
ribonucleoprotein (RNP) complex [13]. There are two non-
structural proteins, NS1 and NS2 that may play a role in
virus replication [14] and a regulatory protein (M2-2) [15].
Although hRSV was discovered more than 50 years ago,
there is no FDA-approved vaccine. In 1966, a vaccine
consisting of formalin-inactivated, parainfluenza virus and
Mycoplasma pneumoniae caused severe bronchiolitis and
pneumonia requiring hospitalization in 80% of vaccinated
children upon hRSV challenge [16]. Tragically, two of the
vaccinated infants succumbed to the symptoms of the dis-
ease [16,17]. Consequently, development of a vaccine is
proceeding cautiously. The existing therapies for the acute
infection are ribavirin [18,19] which has inconsistent clin-
ical results and severe toxic liabilities, and the prophylactic
humanized monoclonal antibody SynagisW (Palivizumab)
that is limited to use in high risk pediatric patients [20].
Ribavirin, a nucleoside anti-metabolite prodrug also
resembles GMP and can decrease cellular GTP pools dueto the inhibition of the enzyme inosine monophosphate
dehydrogenase (IMPDH) [21]. Nevertheless, this decrease
does not completely account for the observed antiviral ac-
tivity as inhibitory effects have been noted on RNA cap-
ping [22] and direct suppressive effect on the polymerase
activity in the case of influenza viruses [23].
To date, screening efforts [24-26] have been used to
discover lead candidate antiviral compounds against
hRSV, which include inhibitors of IMPDH [27,28], viral
fusion [29-32], the ribonucleoprotein (RNP) complex
[33,34], virus attachment [35,36] and a nucleocapsid in-
hibitor [24]. However, many of these inhibitors did not
advance into the clinic due to proper oral formula-
tion for bio-availability [35] strategic reasons [37] and
in vivo efficacy assessment that showed a reduction in
pyrimidine pools rather than a decrease in viral load
[38]. Hence, new drug candidates and treatment therap-
ies are needed to combat hRSV. Toward this goal, we
report herein on the development, optimization and
validation of a 384-well cell-based assay that measures
cytopathic effect (CPE) induced in HEp-2 cells by hRSV
infection, using a luminescent-based detection system
for signal endpoint. The validated assay was used to
screen greater than 313,000 compounds from the Mo-
lecular Libraries Small Molecule Repository (MLSMR)
and resulted in several new lead candidates.
Results
Optimization of media and cell density
Our initial efforts aimed to develop and optimize a high-
throughput assay for efficient screening of small molecule
libraries that measures the virus-induced cytopathic effect
(CPE) in HEp-2 cells. During assay development, we
optimized several parameters such as assay media (pH),
plating density, assay DMSO tolerance, multiplicity of in-
fection (MOI), and positive control drug concentration.
The reagent used to measure CPE was Cell Titer Glo
Luminescent Cell Viability reagent. Cell Titer Glo gene-
rates a luminescent signal directly proportional to the
amount of cellular ATP present which is proportional to
the number of metabolically active cells. We began by de-
termining the medium that would provide optimum virus
infectivity in HEp-2 cells in a high throughput format
(384-well format). After examining Opti-MEM, DMEM
and DMEM/F12 supplemented with FBS concentrations
ranging from 1 to 10%, we determined that complete
DMEM/F12 with 2% FBS was the optimal assay medium
(data not shown). In addition, we examined the pH of
DMEM/F12 assay media. To determine optimum media
pH, HEp-2 cells were resuspended in DMEM/F12 medium
at pHs ranging from 6.8 to 7.8 and plated into 384-well
plates at 3,000 cells per well. One half of the plates (n =192
wells) of each media pH were infected at an multiplicity of
infection (MOI) of 0.2 plaque forming units (pfu) per cell
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was 25 to 30% cell viability in the virus-infected cells at
pH 6.8 and 7.2. Statistically, there was little difference be-
tween a media pH of 7.5 and 7.8 (20% cell viability in
virus-infected cells); therefore, we chose a more biologic-
ally relevant pH of 7.5 as optimal (Figure 1A).
Optimal cell density is necessary to ensure that sufficient
cells are present for adequate endpoint. A signal-to-back-
ground (S/B) ratio of greater than 5 and a signal-to-noise
(S/N) ratio of greater than 10 is acceptable for most HT
screening assays. Therefore, to determine the number of
cells required to optimize S/B and S/N ratios cell density
experiments were performed. We plated 1000, 2000, 4000,
and 6000 HEp-2 cells per well in 384 well plates, infected
the appropriate wells (n =192) with virus at an MOI of 0.2,
incubated for six days, measured luminescence and
determined percent cell viability. As shown in Figure 1B,
1000 cells per well had a S/B of 58.4 as compared to 12Figure 1 Optimization of cell density. A) HEp-2 cells were resuspended
at 3000 cells per well. B) HEp-2 cells were plated into 384-well plates at the
calculate the signal-to-background and signal-to-noise ratios as per the Ma
the indicated cell number per well. The percent cell viability was used to c
TCID50 doses of RSV were added to the appropriate well which correspond
determined by the addition of Cell Titer Glo reagent (Promega). Error barsfor 6000 cells per well. The S/N values ranged from 13 for
1000 cells per well to approximately 19 for 2000, 4000 and
6000 cells per well. In addition to determining the S/B and
S/N ratios we also determined the Z factor [39] of the
plates with the various cell densities (Figure 1C). The Z
factors for the plates containing 1000, 2000, 4000, and
6000 cells per well were 0.75, 0.82, 0.82 and 0.78, respect-
ively (Figure 1C). We chose 2000 cells per well as optimal,
since the S/B was 36.5, the S/N was 19 and the Z factor
was 0.82 (Figure 1B and C).
DMSO effect and virus multiplicity of infection
A critical parameter in assay performance is DMSO tol-
erance since it is used as a compound solvent. To deter-
mine the highest DMSO concentration that the HEp-2
cells could tolerate, we monitored the effect of serial 2-
fold dilutions of DMSO (4% to 0.03%). Inhibition of cell
growth was evaluated relative to uninfected cells andin DMEM/F12 medium at different pHs and plated into 384-well plates
indicated cell number per well. The percent cell viability was used to
terials and Methods. C) HEp-2 cells were plated into 384-well plates at
alculate Z factors as per the Materials and Methods. For all assays 100
s to an MOI of 0.2 infectious particles/cell. Percent cell viability was
indicate the range from triplicate plates.
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indicates there is only a 10% reduction in HEp-2 cell via-
bility with DMSO concentrations up to 1% (Figure 2A).
Thereafter, cell viability declined substantially with in-
creasing concentrations of DMSO as only 30% of the
uninfected cells are viable at 3% DMSO. Moreover,
DMSO concentrations of up to 2% did not inhibit virus-
infectivity. However, we observed a steady decrease in
the infected cell viability above 2% DMSO which
parallels the DMSO toxicity curve and could be due to
the combined result of toxicity and viral infection. Based
on these findings, screening was performed at 0.5%
DMSO final concentration.
To establish the signal dynamic range of the assay, we
ascertained the optimal virus concentration that would
give the largest difference between cells alone (the cell
control) and cells infected with virus (the virus control).
Dilutions of hRSV (MOI = 0.005, 0.01, 0.025, 0.1 and
0.5) were added to HEp-2 cells (2000 cells/well) and lu-
minescence was measured on days 3 to 6 post infection.
MOIs ranging from 0.005 – 0.1 caused CPE in only 20%
of cells (80% cell viability) when determined 6 days post-
infection (Figure 2B). However, HEp-2 cells infected with











































Figure 2 DMSO effect on assay performance and hRSV Long
strain MOI titration. A) Serial 2-fold dilutions of DMSO in assay
media, along with RSV Long strain [MOI = 0.2], were added to 2000
HEp-2 cells in 384 well plates. Six days post-infection, the cytopathic
effect (CPE) of DMSO was assessed using Cell Titer Glo. B) Percent
cell viability versus increasing MOIs on days 3 – 6 post-infection. CPE
was assessed using Cell Titer Glo.Therefore, we determined the optimal concentration of
the virus relative to the cell control was with an MOI of
0.5 on day 6 p.i.
Control drug concentration
The only FDA approved antiviral drug for acute hRSV
infection is ribavirin [18,19]. We used the CPE based
assay to evaluate the metabolically active form of
ribavirin [40] in dose response experiments for EC50 (ef-
ficacy) and CC50 (cytotoxicity). As is shown in Figure 3
we determined an EC50 value of approximately 40 μM as
compared to 41 μM from previously reported EC50
values [41] and an CC50 value of approximately 75 μM.
Given the narrow window between ribavirin efficacy and
toxicity, we chose 35 μM dose of ribavirin as the positive
control drug concentration.
Z-factor analysis and assay performance
As a final parameter to validate the robustness of our
assay, adapt to the HTS platform and assess the quality
of this assay, we performed Z-factor and coefficient of
variation (CV) analyses by running three separate plates
on three days for a total of 9 plates. We plated 2000
HEp-2 cells per well of a 384-well plate and infected half
the plates with hRSV at an MOI of 0.5. We obtained Z
factors greater than 0.8 (0.82 ± 0.02), however, the CVFigure 3 Dose response of ribavirin. HEp-2 cells were plated in
384-well black tissue culture plates at 2,000 cells per well. Ribavirin
or carrier control (DMSO) were diluted to 6x in Complete DMEM/F12
and serially diluted 1:2 resulting in an 8 point dose response dilution
series. (final plate well concentration ranging from 50 uM to 0.39 uM
and a final DMSO concentration of 0.5%). For dose response
screening, cells were infected with a 1:500 dilution of virus (viral
MOI = 0.5). The assay plates were incubated for six days at 37°C,
5% CO2 and 90% relative humidity and the inhibitory effects of the
drug were assessed using Cell Titer Glo. The EC50 value (squares)
was performed in triplicate while the IC50 value (triangles) was
performed in duplicate.
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(24.8 ± 0.01%). We attributed these results to the instabil-
ity of hRSV. For example, during assay development and
early validation, virus stocks retained infectivity for
varying lengths of time from one to six weeks [42]. The
high CV value reflected inconsistency of virus infectivity.
To overcome this problem, we produced frozen hRSV-
infected HEp-2 cells and mixed them at a ratio of 1:100
with uninfected Hep-2 cells. Previously, we showed a
Pearson's correlation of 0.84 of duplicate EC50 values
derived from 92 compounds using frozen hRSV-infected
HEp-2 cells versus high-titer infectious virus. These data
suggested we could use the frozen infected cells as a
source of infectious pathogen [42].
To ascertain the percentage of HEp-2 cells that were
infected with hRSV in our assay we examined them by
flow cytometry. hRSV-infected HEp-2 cells were stained
intracellularly with mouse monoclonals to hRSV. We
determined that 41% of the cells or approximately 820
of 2000 cells per 384 well were infected with hRSV
(Figure 4). Hence, hRSV- infected cells were utilized in
the HT assay to screen the MLSMR.
Compound screen results
A total of 313,816 compounds from the MLSMR were
screened in single dose at 10 μM compound concentra-
tion against hRSV strain Long HEp-2 infected cells. The
average Z-factors were 0.8 ± 0.08 with an average signal
to background of 37.6 ± 6.2 for the single dose screening
campaign. The mean inhibition of the compound wells
was 2.9%. Inhibition values of greater than 22.4% wereFigure 4 FACS analysis of frozen RSV-infected HEp-2 cells. A) Flow cyt
scatter versus fluorescence of HEp-2 cells infected in vitro with RSV strain L
percentage of positive cells in the FACS analysis represents the percentage
applying a forward and side-scatter gate to eliminate dead cells and debris
RSV strain Long. Histograms of fluorescence of cells stained intracellularly w
unstained cells and cells stained with antibody and uninfected cells stainedoutside the calculated noise of the assay defined by the
average percent inhibition plus three times the standard
deviation (3σ ) (Figure 5). We identified 7,583 compounds
that showed greater than 22% CPE inhibition in the pri-
mary cell-based HT screen for a “hit” rate of 2.4%.
The top 2,465 compounds were selected for confirm-
ation screening based on the criteria of greater than or
equal to 50% CPE inhibition. Of the compounds tested
in the confirmatory screen, 409 compounds showed at
least 50% inhibition of CPE and were considered active.
We selected fifty-one compounds, based on potency, se-
lectivity and chemical tractability, for further evaluation
in dose response and measured the difference in viral
titer between non-treated and treated cells in a titer re-
duction assay. The titer reduction assay involves challen-
ging HEp-2 cells with hRSV at a high MOI in the
presence of compound. The progeny virus was serially
diluted 10-fold and the suspension transferred to fresh
HEp-2 cells in 384-well plates. The progeny viral titer
was calculated using the TCID50 method [43]. Of the 51
compounds analyzed by TCID50 analysis, all showed
more than 10-fold reduction in the progeny titer (<-1 of
log reduction) for at least one concentration (Figure 6).
Four general chemotypes (or chemical families) emerged
from the TCID50 analysis. They are represented in
Figure 7. The N-alkylsulfonamides are represented by en-
tries 1-5 and the bis-arylamides and isosteric bis-
arylsulfonamides by entries 6-12. The other two clusters
are both mixed aryl/heterocycles, however one chemotype
is separated by a single linker atom (entries 13 and 14),
while the other is separated by an amide-based linkerometry evaluation of infectivity. Representative dot plots of forward
ong. A minimum of 10000 cells were acquired for each dot plot. The
of RSV positive cells over the live cell population. This was calculated
from the analysis. B) Intracellular staining in HEP-2 cells infected with
ith mouse monoclonal [4 clone blend] to RSV. Controls included
with antibody.
Figure 5 HTS of MLSMR library. High through-put screen of 313,816 compounds in single dose from the NIH MLSMR library against RSV.
Compounds from the library, along with the respiratory syncytial virus, strain Long, frozen-infected HEp-2 cells were added to uninfected HEp-2
cells per well in 384-well plates. Inhibitory effects were assessed after 6 days, as described in Materials and Methods. Reference lines were
calculated from the percent (%) inhibition.
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activities of selected compounds in Figure 7 are sorted by
cluster and by increasing EC50 values within each chem-
ical family.
Inhibition of progeny virus production - hRSV plaque
assay
A plaque assay was used to confirm the antiviral com-































Figure 6 Titration of progeny viruses. Titer of progeny viruses
produced from the cell was measured by TCID50 assay in 384-well
plate format with 4 wells per dilution of virus. Ten (10) μL of 10-fold
serial dilutions of progeny virus containing medium from respective
samples (drug treated or untreated) were used to infect fresh Hep-2
cells in a 384-well format. After 6 days incubation the inhibitory
effects of the compound and drug were assessed using Cell Titer
Glo. A well showing a luminescence signal less than the mean of
the non-infected control signal minus five times the standard
deviation of the control was regarded as positive for infection.sulfonamide and carboxamide functions. These com-
pounds were evaluated for their ability to reduce the
amount of infectious virus produced in cell culture.
HEp-2 cells were infected with hRSV in the presence of
25 μM test compound. Media supernatants were removed
and 10-fold serial-diluted onto a confluent field of unin-
fected, untreated HEp-2 cells, bound, washed, and over-
laid with agarose. After six days, plaques were fixed,
stained, and counted to determine the amount of infec-
tious virus in the original, drugged supernatants (Figure 8).
Compounds with SIDs 93616802 and 93616803 exhibited
a 3-log and 4-log reduction in virus titer, respectively,
while SID 99309097 and SID 99309100 reduced titers 1 to
2 fold. Most interestingly, SID 93616804 exhibited a 6.5-
log reduction from the control in pfu/mL.
Discussion
A whole cell HT assay for the rapid identification of po-
tential inhibitors of hRSV from large compound librar-
ies has been developed, optimized and validated. The
assay is sensitive and robust, with Z factors equal to 0.8,
signal to background greater than 35, and signal to
noise greater than 24. Our cell based assay utilizes the
luminescence signal generated by the amount of ATP
present in the samples to measure the inhibition of
virus-induced cytopathic effects on cells [42]. This CPE-
based assay has an advantage over reporter-based assays
as it can be used to identify inhibitors that target mul-











SI50 TCID50 (log 
reduction)
1 93616802 92 0.5 30.0 58.9 -7.5
2 93575607 42 1.5 5.1 3.4 -7.5
3 99309097 NA 3 33 11 -1.0a
4 93575598 54 12.5 41.8 3.3 -5.1
5 99309100 NA 12.6 33.4 2.7 -2.0a


















7 93575606 NA 4.7 48.4 10.3 -5.0
8 93616795 78 5.0 15.3 3 -7.5
9 93616806 101 5.7 44.8 7.9 -3.4
10 92729866 43 5.9 22.9 3.8 -5.1














12 93616811 45 6.4 40.0 6.3 -7.5
13 93616799 NA 4.5 >50 11.1 -5.0
14 92729864 49 9.5 45.9 4.8 -5.4
15 93616816 49 5.0 25.2 5.1 -7.5
16 93575605 66 5.6 19.3 3.4 -7.5
% INH = percent inhibition; CPE = cytopathic effect; aPlaque reduction (pfu/mL)
Figure 7 Structures and inhibitory activities of selected compounds (μM).
















Figure 8 Plaque reduction assay in HEp-2 cells. RSV strain Long was assayed for its sensitivity to five compounds. Supernatants were
harvested from test (25 μM) or control compound (35 μM) treated RSV-infected HEp-2 cells at a multiplicity of infection (MOI) of 0.1. Serial
dilutions of the supernatants were added to monolayers of HEp-2 cells in 24-well plates. Cells were fixed after 6 days and stained with neutral
red. Plaque reduction assays were performed in triplicate per compound. CC, uninfected cell control; VC, untreated virus-infected control. The
concentration of DMSO in each assay well, including all control wells was 0.5%.
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small molecules from the MLSMR at 10 μM for inhib-
ition of hRSV in vitro. We identified more than 7,500
compounds that showed at least 22% inhibition of CPE
for a hit rate of 2.4%. We had a confirmation hit rate of
16.5% as 409 compounds out of more than 2,400
compounds screened in dose response/cytotoxicity
assays met our criteria of activity: the efficacy, EC50
value of less than 15 μM and with toxicity to efficacy,
SI50 of greater than 3.
The compounds presented in Figure 7 represent a
selected set of compounds possessing sulfonamide and
carboxamide functions and were chosen on the basis of
several considerations including the fact that these
compounds displayed at least a 3-log reduction in virus
as determined by preliminary TCID50 analysis. Further-
more, three compounds displayed at least a three-fold
reduction from the control (pfu/mL) in a plaque reduc-
tion assay.
To begin to probe the mechanism of action of the
sulfonylpyrrolidines, the window of inhibitory activity in
the cell-based assay was refined. Potency of compounds
over time following infection was examined to ascertain
early (entry) or late (replication) antiviral activity in the
virus life cycle [44]. In the time of addition study, HEp-2
cells were infected with hRSV strain Long at an MOI of
0.1 at time point 0 and test compounds or ribavirin were
added to plates one hour before infection to 24 hours after
infection. Six days later, CPE was assessed using Cell-Titer
Glo as an endpoint reagent. An N-alkylsulfonamide com-
pound with SID 99309100 demonstrated a decrease in ef-
ficacy when added at each time point from 0-5 hours p.i.
This profile could be due to the inhibition of one or more
early virus life cycle steps (entry, post-entry, or early-stage
infection processes suggesting this chemotype inhibitsearly infection events, characterized by viral attachment,
uptake, fusion or initial transcription.
There are several promising candidates in various
stages of clinical development that could meet the need
for the Paramyxovirus antiviral market; however, drug
resistance may lead to a need for additional compounds
in the pipeline. Studies in the laboratory reveal that re-
sistant viruses arise after 15-20 days in culture in the
presence of the palivizumab. Sequence analysis reveals
that a single amino acid change in the fusion protein
produces a virus that is as fit as the wild type [45-47].
While there are no reports of Synagis resistant viruses
circulating in the population, a palivizumab-resistant
hRSV infection from an infant has been documented
[48]. Two mutants in the F protein encompassing amino
acids 262-276 conferred resistance to palivizumab. Thus,
there has been promising data to suggest that hRSV
polymerase and fusion proteins are pharmacological
targets that merit the development of multiple drugs to
abort infection and circumvent drug resistance.Conclusions
The aim of this study was to develop, validate and optimize
a cell-based HT assay for identification of new hRSV anti-
viral lead compounds from the MLSMR. Primary and sec-
ondary screening of the library has led to the discovery of
several compounds with SI values of greater than 3. Dose
response and cytotoxicity assays indicate that at least one
of the scaffolds met our activity criteria for further SAR
evaluation: an efficacy EC50 value of < 15 μM and toxicity
to efficacy SI of >3. This scaffold has not been previously
identified as having anti-viral activity. Subsequently, several
analogues have been synthesized for additional testing,
analyzed in-depth to evaluate SAR and contribute to probe
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have been disclosed in a separate publication [44].
Methods
Cell growth conditions and media
HEp-2 cells (ATCC CCL-23, American Tissue Culture
Type) were maintained as adherent cell lines in Opti-
MEM1W (Invitrogen) with 2 mML-glutamine and 10%
fetal bovine serum (FBS) at 37°C in a humidified 5%
CO2 atmosphere. Cells were passaged as needed and
harvested from flasks using 0.25% trypsin-EDTA.
Assay media
Preparation of Complete DMEM/F12 was as follows:
50 mL Pen/Strep/Glutamine (Gibco) was added to four
liters of room temperature DMEM/F12 (Sigma) and the
pH adjusted to 7.5 using 1 N NaOH. The medium was
sterile filtered (0.2 μm) and 10 mL of HI-FBS (Gibco)
was added per 500 mL of media.
hRSV culture
Human respiratory syncytial virus (hRSV) strain Long
(ATCC VR-26) was used for assays. Virus was serially
diluted and a dilution of 1:10 was used to amplify the
seed stock. Briefly, a TCID50 format of 10-fold serial
dilutions (from 10-1 to 10-7) was used to dilute the virus.
HEp-2 cells grown in a 384-well plate were infected with
hRSV. Plates were incubated at 37°C, 5% CO2, and 90%
relative humidity for four days. Supernatant from the
384-well plate’s highest viral dilution was used to infect
a single well of HEp-2 cells in a 6-well plate format
containing approximately 2.4 × 106 cells/well. A two mL
volume of Complete-Opti-MEM1 (C-Opt1) (Gibco)
containing 10% FBS per well was removed and replaced
with 100 μL of C-Opt1. Virus culture supernatant from
the 384-well TCID50 was added to 100 μl C-Opt1 and
incubated at 37°C, 5% CO2, and 90% relative humidity
for 1.5 h rotating every 30 min to facilitate infection.
The media was removed and replaced with 2 mL of
C-Opt1 and incubated at 37°C, 5% CO2, and 90% rela-
tive humidity. After 72 h, the supernatant was removed
and the cell debris pelleted by centrifugation at 300 × g,
5 min, at 18°C. One T-175, containing 4.78 × 106 HEp-2
cells was incubated overnight and used to amplify the
virus. After 18 h, media was removed, cells were washed
with 10 mL Complete-DMEM/F12 (2% FBS, 1.25% P/S/
G, pH 7.5) and replenished with 4 mL C-DMEM/F12. A
100 μL sample of clarified hRSV was added to a T-175
and incubated for 1.5 h at 37°C, 5% CO2, and 90% rela-
tive humidity. The media was removed and replenished
with 25 mL of C-DMEM/F12, and incubated at 37°C, 5%
CO2, and 90% relative humidity for 48 h. The media was
transferred to a 50 mL conical tube and cell debris
pelleted at 300 × g, 5 min, at 18°C. Trehalose and FBSwere added to a final concentration of 10% (v/v) each
for preservation [49] and the supernatant was aliquoted
(1 mL per tube), fast frozen in 100% EtOH/dry ice and
stored at –150°C. Virus stocks titers were quantified in
HEp-2 cells using an agarose overlay plaque method.
The titer of the virus was 1.0 × 107 pfu/mL.
Infectious material: Frozen infected virus cell preparation
Preparation of the frozen hRSV-infected HEp-2 cells has
been previously described [42]. Briefly, a T-225 flask
containing 3.0 × 108 HEp-2 cells in 30 mL Complete
DMEM/F12, pH 7.5, was grown to 95% confluence. Two
mL hRSV (strain Long) containing 1 × 107 pfu/mL was
added to the flask and incubated for 18 – 20 h at 37°C,
5% C02, 90% relative humidity. After incubation, the
medium was aspirated and the cells washed with 10 mL
PBS without Mg2+ or Ca2+. Cells were harvested from
flasks using 0.25% trypsin-EDTA. Cells were centrifuged
at 300 × g for 10 min and re-suspended in 95% FBS, 5%
DMSO at a concentration of 2 × 106 cells/mL. The cells
were determined to be at least 99% viable. The cells were
aliquoted in 1 mL aliquots, rate frozen at –1°C/min to -
80°C and stored at –150°C. Viability was also evaluated
when thawed and determined to be at least 98.5%. We
confirmed the percentile of infected cells in two ways;
immunostaining and cell counting using FACS and a
limited dilution methodology.
FACS analysis of frozen infected cells
Frozen hRSV-infected and un-infected HEp-2 cells (2 ×
106 cells) were centrifuged at 300 × g for 5 min and the
supernatant removed. Cell pellets (uninfected and hRSV-
infected) were fixed in 1 mL of 4% paraformaldehyde for
15 min on ice. Cells were washed twice in 1 mL staining
buffer (1X - Dulbecco's Phosphate Buffered Saline Solution
[DPBS], 2% FCS) centrifuging at 300 × g for 5 min between
washes. Cells were resuspended in 1 mL of staining buffer
and 2 × 105 cells were aliquoted into 12 × 75 mm tissue
culture tubes. Dilutions (1:5000, 1:2000, 1:1000, 1:500) of
mouse monoclonal [4 clone blend] to hRSV(Abcam) was
added to the cells, incubated for 30 min on ice and washed
twice in 3.5 mL staining buffer. Secondary antibody (goat
anti-mouse IgG/M conjugated to FITC (BD Pharmingen)
was added, incubated for 30 min on ice and washed twice
with 3.5 mL DPBS. Cells were resuspended in 0.4 mL
DPBS and analyzed on a FACSCalibur flow cytometer.
Controls included unstained cells, cells stained with either
the primary or secondary antibody and uninfected cells
stained with both antibody reagents.
Compound libraries and controls
The positive control drug for this assay, ribavirin (MP
Biomedicals, Solon, OH) was solubilized in DMSO,
diluted and added to the assay plates as described for
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35 μM. All wells contained 0.5% DMSO.
The MLSMR is a library of biologically relevant small
organic molecules that has been utilized for HTS as part
of the NIH Roadmap initiative, the Molecular Libraries
Production Center Network (MLPCN). This library has
been updated and expanded since the initiation of the pro-
gram in 2005. Compounds were solubilized at 10 mM in
DMSO and all compounds were diluted in assay media for
a final concentration of 10 μM in the screen. The concen-
tration of DMSO in each assay well, including all control
wells was 0.5%.
Compound preparation
For single dose screening in a 384 well plate format,
compounds or carrier control (DMSO) were diluted to
6× in Complete DMEM/F12 using a Biomek FX and 5
μL was transferred to the assay plate. Cells were added
to the plate in 25 uL of media using a Thermo/Matrix
Wellmate. Final plate well concentration was 10 μM
compound, 2,000 cells, and 0.5% DMSO in a total vol-
ume of 30 uL.
For dose response screening in a 384 well plate format,
compounds or carrier control (DMSO) were diluted to
6× in Complete DMEM/F12 using a Biomek FX and 5
μL was dispensed to assay plates (3% DMSO). Test
compounds were serially diluted in a plate to plate
matrix or “stacked plate” matrix. All 320 compounds in
a source plate were diluted together resulting in a 10
point dose response dilution series proceeding vertically
through a stack of plates with the high dose plate on top
and the low dose plate on the bottom (final plate well
concentration ranging from 50 μM to 0.097 μM and a
final DMSO concentration of 0.5%).
Assay setup
Compounds or carrier control (DMSO) were diluted to
6x in C-DMEM/F12 and 5 μL was dispensed to 384-well
assay plates (3% DMSO or 60 μM compound in 3%
DMSO). Twenty five μL of uninfected HEp-2 cells were
plated in the cell control wells. Frozen hRSV-infected
cells were combined with uninfected HEp-2 cells at a
1:100 ratio. Twenty five μL of the cell mixture was added
to the virus control and compound wells. All cell plating
was conducted using a Matrix WellMate and cells were
maintained at room temperature with stirring during the
plating process. The assay plates were incubated for six
days at 37°C, 5% CO2 and 90% relative humidity.
Endpoint read
Following the six day incubation period, the assay plates
were equilibrated to room temperature for 30 min. An
equal volume (30 μL) of Cell Titer-Glo reagent (Promega
Inc.) was added to each well using a WellMate (Matrix,Hudson, NH) and the plates were incubated for an add-
itional 10 min at room temperature. At the end of the
incubation, luminescence was measured using a multi-
label reader (Envision, PerkinElmer, Wellesley, MA) with
an integration time of 0.1 s.
Data analysis
HTS data were analyzed using ActivityBase software
(IDBS, Inc., Guildford, UK). Antiviral activity is
described as percent CPE inhibition = 100*((lumines-
cence compound well minus median luminescence virus
control)/ (median luminescence cell control minus me-
dian luminescence virus control)). Percent viability =
100 * luminescence compound well/median lumines-
cence cell control. An active compound, or “hit,” was
defined as a compound that exhibited a % CPE inhibition
of >22% without compromising cell viability. Two dose-
response curves were calculated for each substance. One
assessed % CPE inhibition at each dose (EC50); the other
assessed cytotoxicity at each dose (CC50). EC50 values
(for % CPE inhibition) and CC50 values were calculated
using the 4-parameter Levenburg-Marquardt algorithm
with parameter A locked at 0 and parameter B locked at
100. Standard deviation, normalized chi2, and Hill slope
were used to evaluate the curves. Values were not
extrapolated beyond the tested range of concentrations.
The selective index (SI) was calculated as SI = CC50/
EC50. The criteria for determining compound activity
are based on its SI. Compounds with an SI value of >3
were defined as active, whereas compounds that
exhibited an SI value less than 3 were defined as
inactive.
Thirty-two control wells containing cells only and 24
wells containing cells and virus were included on each
assay plate and used to calculate Z factors for each plate
and to normalize the data on a per plate basis. Eight
ribavirin positive control wells were included on each
plate for quality control purposes but were not used in Z
calculations.
The Z factor values were calculated from 1 minus
(3*standard deviation of cell control plus 3* standard de-
viation of the virus control / [mean cell control signal
minus mean virus control signal [39]. The signal-to-
background (S/B) was calculated from mean cell control
signal divided by the mean virus control signal. The
signal-to-noise (S/N) was calculated from mean cell con-
trol signal minus mean virus control signal divided by
the standard deviation of the cell control signal minus
the standard deviation of the virus control signal [39].
Titration of progeny viruses
Titer of progeny viruses produced from the cell was
measured by TCID50 assay in 384-well plate format with
4 wells per dilution of virus. Ten μL of 10-fold serial
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spective samples (drug treated or untreated) were used
to infect fresh Hep-2 cells in a 384-well format. The cell
plates were incubated at 37°C, 5% CO2, and high hu-
midity for an additional 6 days. The Cell Titer Glo assay
was used to determine viability of the cells. A well
showing a luminescence signal less than the mean of
the non-infected control signal minus five times the
standard deviation of the control was regarded as posi-
tive for infection.
Plaque assays - compound preparation
Compounds or carrier control (DMSO) were diluted in
Complete DMEM/F12 and 2 mL per well was dispensed
to 6-well assay plates (final plate well concentration
was 25 μM, ribavirin; 35 μM and final DMSO concentra-
tion 0.5%).
Preparation of HEp-2 cells and plaque assay setup
HEp-2 cells were harvested and resuspended to 500,000
cells per mL in Complete DMEM/F12 and seeded in 6
well tissue culture plates at 1,000,000 cells per well in
2 mL Complete Optimem1 and incubated 24 hours at
37°C, 5% CO2, 90% relative humidity. The media was
aspirated from the wells, 0.5 mL hRSV Long strain
(MOI of 0.1) diluted using C-DMEM/F12 was added
and the plates incubated at 37°C, 5% CO2, rotating every
20 min. to facilitate infection. After 2 hours, the virus
supernatant was aspirated and each well was washed
with 3 mL of 1X PBS. Compounds were diluted in C-
DMEM/F12 media to give a final concentration of
25 μM, added to assay plates and incubated at 37°C, 5%
CO2 and 90% relative humidity. After 48 h, the super-
natant (hRSV/compound/media; 1.6 mL) was removed,
flash frozen on dry ice, and stored at –80°C.
HEp-2 cells in Complete Optimem1were seeded in 24
well tissue culture plates at 400,000 cells per well in
0.5 mL and incubated 24 h at 37°C, 5% CO2. The super-
natant (hRSV/compound/ media) was removed from -
80°C and thawed on ice. The supernatants were serially
diluted in Complete DMEM/F12 media (10-1 to 10-4).
The media was aspirated from the 24 well plates, 0.2 mL
of each supernatant dilution was added to each well and
the plates incubated at 37°C, 5% CO2, rotating every
20 min. to facilitate infection. After 2 h, each well was
washed one time with 1X PBS followed by the addition
of 0.5 mL 1% Avicel per well. The assay plates were
incubated for six days at 37°C, 5% CO2 and 90% relative
humidity.
Staining of virus plaques
Following the six day incubation period, the Avicel over-
lay was aspirated, washed with 0.5 mL of 1X PBS, and
fixed with 0.5 mL of 4% paraformaldehyde per well. Theassay plates were incubated at 4°C for 24 h. The
paraformaldehyde was aspirated, each well washed with
1 mL deionized water, and stained with 1 mL of 0.05%
neutral red with periodic shaking for 10 minutes at
room temperature. The neutral red was aspirated and
the plates briefly inverted without lids on paper towels
for drying.
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